高分化/去分化脂肪肉瘤的疾病特征及免疫相关治疗的研究进展

doi:10.11904/j.issn.1002-3070.2024.04.011

摘要/Abstract

摘要： 脂肪肉瘤是常见的软组织恶性肿瘤,具有多种组织学分型,其中高分化脂肪肉瘤和去分化脂肪肉瘤是脂肪肉瘤发病的最大亚群。经常规方式治疗,去分化脂肪肉瘤患者通过常规方式治疗的5年生存率并未得到明显改善。近年来,免疫治疗在黑色素瘤和肺癌等肿瘤中显示出明显的疗效,进而在高分化脂肪肉瘤和去分化脂肪肉瘤中开展了广泛的研究,本文总结了高分化脂肪肉瘤和去分化脂肪肉瘤的临床及遗传学特点,常规的治疗方式以及免疫治疗在脂肪肉瘤中的应用,包括免疫检查点抑制剂、过继细胞疗法、溶瘤病毒、癌症疫苗和免疫治疗联合其他治疗方案。整合脂肪肉瘤免疫相关治疗方案是目前亟待解决的问题,也为临床工作了解脂肪肉瘤及新型管理治疗策略提供广阔思路。

关键词: 高分化/去分化脂肪肉瘤, 疾病特征, 免疫治疗

Abstract: Liposarcoma is a common soft tissue malignant tumor with multiple histological types,among which well-differentiated liposarcoma and dedifferentiated liposarcoma are the largest subgroups of liposarcoma. After conventional treatment,the 5-year survival rate of patients with dedifferentiated liposarcoma has not been significantly improved. In recent years,immunotherapy has shown significant efficacy in tumors such as melanoma and lung cancer,and has been widely studied in well-differentiated liposarcoma and dedifferentiated liposarcoma. This article summarizes the clinical and genetic features of well-differentiated liposarcoma and dedifferentiated liposarcoma,conventional treatment methods,and the application of immunotherapy in liposarcoma,including immune checkpoint inhibitors,adoptive cell therapy,oncolytic viruses,cancer vaccines,and immunotherapy combined with other treatment options. Integrating immune-related treatment options for liposarcoma is an urgent problem to be solved,and it also provides broad ideas for clinical work to understand liposarcoma and new management and treatment strategies.

Key words: Well-differentiated/dedifferentiated liposarcoma, Disease characteristics, Immunotherapy

中图分类号:

徐耀杰, 常易航, 莫匹满, 包俊杰. 高分化/去分化脂肪肉瘤的疾病特征及免疫相关治疗的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 278-282.

XU Yaojie, CHANG Yihang, MO Piman, BAO Junjie. Research progress on disease characteristics and immune-related treatment of well-differentiated/dedifferentiated liposarcoma[J]. Journal of Practical Oncology, 2024, 38(4): 278-282.

参考文献

1 Sbaraglia M,Bellan E,Dei Tos AP.The 2020 WHO classification of soft tissue tumours:news and perspectives[J].Pathologica,2021,113(2):70-84.
2 Thway K.Well-differentiated liposarcoma and dedifferentiated liposarcoma:an updated review[J].Semin Diagn Pathol,2019,36(2):112-121.
3 Thway K,Jones RL,Noujaim J,et al.Dedifferentiated liposarcoma:updates on morphology,genetics,and therapeutic strategies[J].Adv Anat Pathol,2016,23(1):30-40.
4 Zhou MY,Bui NQ,Charville GW,et al.Treatment of de-differentiated liposarcoma in the era of immunotherapy[J].Int J Mol Sci,2023,24(11):9571.
5 Kim YJ,Yu DB,Kim M,et al.Adipogenesis induces growth inhibition of dedifferentiated liposarcoma[J].Cancer Sci,2019,110(8):2676-2683.
6 Resag A,Toffanin G,Benešová I,et al.The immune contexture of liposarcoma and its clinical implications[J].Cancers,2022,14(19):4578.
7 Dang TN,Tiongco RP,Brown LM,et al.Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma[J].BMC Cancer,2022,22(1):300.
8 Lee A TJ,Thway K,Huang PH,et al.Clinical and molecular spectrum of liposarcoma[J].J Clin Oncol,2018,36(2):151-159.
9 Zhou S,Zhang C,Zhang Z,et al.A novel HMGA2:KITLG fusion in a dedifferentiated liposarcoma with amplification of MDM2 and HMGA2[J].Genes Chromosomes Cancer,2023,63:e23200.
10 Lu J,Wood D,Ingley E,et al.Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma[J].Molecular Biology Reports,2021,48(4):3637-3647.
11 Wang Y,Hu L,Wang J,et al.HMGA2 promotes intestinal tumorigenesis by facilitating MDM2-mediated ubiquitination and degradation of P53[J].J Pathol,2018,246(4):508-518.
12 Denis C J,Deiteren K,Hendriks D,et al.Carboxypeptidase M in apoptosis,adipogenesis and cancer[J].Clin Chim Acta,2013,415:306-316.
13 Mashima E,Sawada Y,Nakamura M.Recent advancement in atypical lipomatous tumor research[J].Int J Mol Sci,2021,22(3):994.
14 Suarez-Kelly LP,Baldi GG,Gronchi A.Pharmacotherapy for Liposarcoma:current state of the art and emerging systemic treatments[J].Expert Opin Pharmacother,2019,20(12):1503-1515.
15 von Mehren M,Kane JM,Agulnik M,et al.Soft tissue sarcoma,version 2.2022,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(7):815-833.
16 Tanaka K,Ozaki T.Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas:jcog bone and soft tissue tumor study group[J].Jpn J Clin Oncol,2021,51(2):180-184.
17 Seddon B,Strauss SJ,Whelan J,et al.Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas(GeDDiS):a randomised controlled phase 3 trial[J].Lancet Oncol,2017,18(10):1397-1410.
18 Schöffski P,Chawla S,Maki RG,et al.Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma:a randomised,open-label,multicentre,phase 3 trial[J].Lancet,2016,387(10028):1629-1637.
19 Cassinelli G,Pasquali S,Lanzi C.Beyond targeting amplified MDM2and CDK4 in well differentiated and dedifferentiated liposarcomas:from promise and clinical applications towards identification of progression drivers[J].Frontiers in Oncology,2022,12:965261.
20 Tan DS,Bedard PL,Kuruvilla J,et al.Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy[J].Cancer Discov,2014,4(5):527-537.
21 Gounder MM,Razak AA,Somaiah N,et al.Selinexor in advanced,metastatic dedifferentiated liposarcoma:a multinational,randomized,double-blind,placebo-controlled trial[J].J Clin Oncol,2022,40(22):2479-2490.
22 Abdul Razak AR,Bauer S,Suarez C,et al.Co-targeting of MDM2 and CDK4/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma:results from a proof-of-concept,phase Ib study[J].Clin Cancer Res,2022,28(6):1087-1097.
23 Song Z,Lu L,Gao Z,et al.Immunotherapy for liposarcoma:emerging opportunities and challenges[J].Future Oncol,2022,18(30):3449-3461.
24 Italiano A,Bellera C,D′Angelo S.PD1/PD-L1 targeting in advanced soft-tissue sarcomas:a pooled analysis of phase II trials[J].J Hematol Oncol,2020,13(1):55.
25 Somaiah N,Conley AP,Parra ER,et al.Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas:a single-withcentre phase 2 trial[J].Lancet Oncol,2022,23(9):1156-1166.
26 D′Angelo SP,Mahoney MR,Van Tine BA,et al.Nivolumab or without ipilimumab treatment for metastatic sarcoma(Alliance A091401):two open-label,non-comparative,randomised,phase 2 trials[J].Lancet Oncol,2018,19(3):416-426.
27 Toulmonde M,Brahmi M,Giraud A,et al.Trabectedin ius durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma(TRAMUNE):an open-label,multicenter phase Ib study[J].Clin Cancer Res,2022,28(9):1765-1772.
28 Snow H,Mitchell C,Hendry S,et al.Characterising the immune microenvironment in liposarcoma,its impact on prognosis and the impact of radiotherapy[J].J Surg Oncol,2021,123(1):117-126.
29 You Y,Guo X,Zhuang R,et al.Activity of PD-1 inhibitor combined with anti-angiogenic therapy in advanced sarcoma:a single-center retrospective analysis[J].Front Mol Biosci,2021,8:747650.
30 Mullinax JE,Hall M,Beatty M,et al.Expanded tumor-infiltrating lymphocytes from soft tissue sarcoma have tumor-specific function[J].J Immunother,2021,44(2):63-70.
31 Ahmed N,Brawley VS,Hegde M,et al.Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J].J Clin Oncol,2015,33(15):1688-1696.
32 Kaufman HL,Kohlhapp FJ,Zloza A.Oncolytic viruses:a new class of immunotherapy drugs[J].Nat Rev Drug Discov,2016,15(9):660.
33 Kelly CM,Antonescu CR,Bowler T,et al.Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab:a phase 2 clinical trial[J].JAMA Oncol,2020,6(3):402-408.
34 Smith H G,Mansfield D,Roulstone V,et al.PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma[J].Clin Cancer Res,2019,25(11):3443-3454.
35 Constantino J,Gomes C,Falcão A,et al.Dendritic cell-based immunotherapy:a basic review and recent advances[J].Immunol Res,2017,65(4):798-810.
36 Pollack SM The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients[J].Expert Rev Vaccines,2018,17(2):107-114.
37 Somaiah N,Chawla SP,Block MS,et al.A phase 1b study evaluating the safety,tolerability,and immunogenicity of CMB305,a lentiviral-based prime-boost vaccine regimen,in patients with locally advanced,relapsed,or metastatic cancer expressing NY-ESO-1[J].Oncoimmunology,2020,9(1):1847846.

[1]	赵璐, 张正凤, 王大臻, 杨柳, 刘泽, 娄长杰. 免疫治疗在实体瘤中的应用现状[J]. 实用肿瘤学杂志, 2024, 38(1): 55-61.
[2]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[3]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[4]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[5]	李娟, 刘家仁. 胃癌免疫治疗的研究现状及进展[J]. 实用肿瘤学杂志, 2023, 37(4): 372-376.
[6]	李路桥, 邹征云. 恶性黑色素瘤免疫治疗超进展研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 144-148.
[7]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[8]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[9]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[10]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[11]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[12]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[13]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[14]	童曼琳, 尚茹茹, 刘晓红. PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 278-282.
[15]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.